Lei Yang | Oncology | Best Researcher Award

Published on by Best Achievements

Prof. Lei Yang | Oncology | Best Researcher Award

Prof. Lei Yang | Guangzhou Medical University | China

Prof. Lei Yang, Ph.D. supervisor at Guangzhou Medical University, is a distinguished researcher specializing in respiratory disease biomarkers and epidemiology. Recognized as a Guangdong “Special Support Plan” Young Talent, he has led multiple NSFC projects, contributed to national R&D programs, and authored over 69 publications with an H-index of 27. His innovations include patents, software copyrights, and a lung cancer detection kit, significantly advancing early diagnosis and precision medicine. He also actively serves on professional committees, contributing to cancer research and public health.

Profiles

Scopus 
Orcid
Google Scholar 

Early Academic Pursuits

Prof. Lei Yang demonstrated strong academic promise early in his career, pursuing studies in biomedical sciences and respiratory medicine. His scholarly journey led him to specialize in biomarker screening and epidemiology, laying the foundation for impactful research in respiratory diseases. His early academic training not only strengthened his expertise in data analysis and disease mechanisms but also prepared him for future leadership roles in medical research and innovation.

Professional Endeavors

Currently a Professor at Guangzhou Medical University and PhD supervisor, Prof. Yang has made significant professional strides in the field of respiratory disease research. Recognized as a Guangdong “Special Support Plan” Young Talent, he has successfully led five NSFC projects, participated in national key R&D programs, and collaborated on major initiatives such as the Precision Medicine Research Special Project. His professional journey reflects a balance of teaching, mentoring, and high-impact research.

Contributions and Research Focus

Prof. Yang’s research focus lies in the screening of biomarkers for respiratory diseases, with special emphasis on lung cancer early detection and high-risk population identification. His team systematically explored the diagnostic value of plasma exosomal non-coding RNAs, leading to the development of a detection kit for clinical application. Moreover, his genome-wide association studies (GWAS) identified novel genetic susceptibility loci, enriching the understanding of lung cancer pathogenesis and paving the way for precision screening and treatment strategies.

Impact and Influence

The impact of Prof. Yang’s work is evident in both scientific advancement and clinical practice. With over 69 publications, including articles in prestigious journals like the American Journal of Respiratory and Critical Care Medicine, his research has been widely cited, achieving an H-index of 27. His contributions have advanced early diagnostic methods, enhanced understanding of genetic risk factors, and influenced public health strategies for respiratory diseases. His achievements continue to shape the future of oncology and respiratory medicine in China and beyond.

Research Skills

Prof. Yang is proficient in biomarker discovery, molecular epidemiology, genome-wide association studies (GWAS), and large-scale data analysis. His expertise extends to the design and implementation of cohort studies, as seen in his involvement in the South China chronic disease prospective cohort project. Additionally, his ability to integrate laboratory research with clinical application demonstrates strong translational research skills that contribute to real-world healthcare solutions.

Awards and Honors

Prof. Yang has received several prestigious honors, including the Ministry of Education Natural Science Second Prize. His recognition as a Guangdong “Special Support Plan” Young Talent underscores his leadership in medical research. He also holds two patents and three software copyrights, reflecting his innovative contributions to respiratory health diagnostics. These accolades highlight both his scientific excellence and his role as a pioneer in translational medicine.

Legacy and Future Contributions

Prof. Yang’s legacy is being built through his groundbreaking work in lung cancer diagnostics and biomarker innovation. His future contributions are likely to further advance precision medicine, strengthen population-based cohort studies, and drive clinical applications of novel biomarkers. By integrating cutting-edge genomic research with practical medical solutions, Prof. Yang is set to leave a lasting mark on respiratory disease prevention, diagnosis, and treatment, inspiring the next generation of medical researchers and innovators.

Publications Top Notes

Title: A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese
Journal: Nature Genetics 43 (8), 792–796 (2011)
Citations: 432
Authors: Z Hu, C Wu, Y Shi, H Guo, X Zhao, Z Yin, L Yang, J Dai, L Hu, W Tan, Z Li, …

Title: Overexpression of lncRNA IGFBP4–1 reprograms energy metabolism to promote lung cancer progression
Journal: Molecular Cancer 16 (1), 154 (2017)
Citations: 130
Authors: B Yang, L Zhang, Y Cao, S Chen, J Cao, D Wu, J Chen, H Xiong, Z Pan, L Yang, …

Title: A functional polymorphism at microRNA-629-binding site in the 3′-untranslated region of NBS1 gene confers an increased risk of lung cancer in Chinese
Journal: Carcinogenesis 33 (2), 338–347 (2012)
Citations: 107
Authors: L Yang, Y Li, M Cheng, D Huang, J Zheng, B Liu, X Ling, Q Li, X Zhang, …

Title: MicroRNA-152 targets DNA methyltransferase 1 in NiS-transformed cells via a feedback mechanism
Journal: Carcinogenesis 34 (2), 446–453 (2013)
Citations: 91
Authors: W Ji, L Yang, J Yuan, L Yang, M Zhang, D Qi, X Duan, A Xuan, W Zhang, …

Title: Common genetic variation in ETV6 is associated with colorectal cancer susceptibility
Journal: Nature Communications 7 (1), 11478 (2016)
Citations: 89
Authors: M Wang, D Gu, M Du, Z Xu, S Zhang, L Zhu, J Lu, R Zhang, J Xing, X Miao, L Yang, …

Title: Identification of three circular RNA cargoes in serum exosomes as diagnostic biomarkers of non–small-cell lung cancer in the Chinese population
Journal: The Journal of Molecular Diagnostics 22 (8), 1096–1108 (2020)
Citations: 85
Authors: J Xian, W Su, L Liu, B Rao, M Lin, Y Feng, F Qiu, J Chen, Q Zhou, Z Zhao, L Yang, …

Title: Association between chronic obstructive pulmonary disease and lung cancer: a case-control study in Southern Chinese and a meta-analysis
Journal: PLoS One 7 (9), e46144 (2012)
Citations: 81
Authors: H Wang, L Yang, L Zou, D Huang, Y Guo, M Pan, Y Tan, H Zhong, W Ji, …

Title: Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations
Journal: Carcinogenesis 33 (12), 2409–2416 (2012)
Citations: 79
Authors: J Zheng, L Jiang, L Zhang, L Yang, J Deng, Y You, N Li, H Wu, W Li, J Lu, …

Title: A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer
Journal: The American Journal of Human Genetics 91 (2), 384–390 (2012)
Citations: 79
Authors: B Liu, L Yang, B Huang, M Cheng, H Wang, Y Li, D Huang, J Zheng, Q Li, …

Title: NFκB1 and NFκBIA Polymorphisms Are Associated with Increased Risk for Sporadic Colorectal Cancer in a Southern Chinese Population
Journal: PLoS One 6 (6), e21726 (2011)
Citations: 79
Authors: S Song, D Chen, J Lu, J Liao, Y Luo, Z Yang, X Fu, X Fan, Y Wei, L Yang, …

Title: The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in southern and eastern Chinese populations
Journal: Human Mutation 32 (11), 1299–1308 (2011)
Citations: 71
Authors: J Lu, L Yang, H Zhao, B Liu, Y Li, H Wu, Q Li, B Zeng, Y Wang, W Ji, …

Title: A functional copy number variation in the WWOX gene is associated with lung cancer risk in Chinese
Journal: Human Molecular Genetics 22 (9), 1886–1894 (2013)
Citations: 68
Authors: L Yang, B Liu, B Huang, J Deng, H Li, B Yu, F Qiu, M Cheng, H Wang, …

Title: A Sequence Polymorphism in miR-608 Predicts Recurrence after Radiotherapy for Nasopharyngeal Carcinoma
Journal: Cancer Research 73 (16), 5151–5162 (2013)
Citations: 61
Authors: J Zheng, J Deng, M Xiao, L Yang, L Zhang, Y You, M Hu, N Li, H Wu, W Li, …

Title: A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression
Journal: Carcinogenesis 34 (10), 2292–2299 (2013)
Citations: 51
Authors: M Cheng, L Yang, R Yang, X Yang, J Deng, B Yu, D Huang, S Zhang, …

Conclusion

Prof. Lei Yang is a distinguished researcher whose work on respiratory disease biomarkers and lung cancer early detection has made significant scientific and clinical impact. With an impressive record of 69 publications, H-index of 27, multiple patents, and national-level projects, he has demonstrated innovation and leadership in advancing precision medicine. While greater international collaborations and industry partnerships could further enhance his global presence, his strong achievements make him highly suitable for the Research for Best Researcher Award.

Dukagjin Blakaj | Oncology | Best Researcher Award

Published on by Best Achievements

Prof. Dr. Dukagjin Blakaj | Oncology | Best Researcher Award

Prof. Dr. Dukagjin Blakaj | The Ohio State University | United States

Dr. Dukagjin M. Blakaj is a visionary leader in radiation oncology, currently serving as the Drs. Malati and Ganesh Potdar Endowed Professor and Vice Chair of Clinical Operations at The Ohio State University Comprehensive Cancer Center. Renowned for advancing proton therapy and translational cancer research, he has overseen exponential growth in departmental faculty, revenue, and NIH funding since joining in 2013. His leadership has transformed clinical operations, implemented strategic innovations, and significantly expanded clinical trial participation. Dr. Blakaj has mentored numerous faculty and fellows, initiated multi-disciplinary research collaborations, and secured millions in philanthropic and research funding. An influential educator and administrator, he also directs fellowships in Head & Neck, CNS/Pediatric, and IORT radiation oncology. Beyond his institutional impact, he serves on national committees and journal boards, shaping the future of cancer research and care. His work exemplifies excellence in clinical innovation, academic mentorship, and collaborative leadership across the oncology landscape.

Profile

Scopus
Orcid
Google Scholar

Education

Dr. Dukagjin Blakaj holds a distinguished academic background with dual advanced degrees in medicine and science. He earned his M.D. and Ph.D. in Biochemistry from the Albert Einstein College of Medicine, where he also completed a Master of Science in Biochemistry. Prior to that, he obtained both his Master of Arts and Bachelor of Arts degrees in Chemistry and Molecular Biology & Biophysics from Wesleyan University. His academic excellence is reflected in numerous accolades, including the Rudin Scholarship and Dean’s Recognition Award. He completed his internship in internal medicine at Mount Sinai Beth Israel Medical Center and a residency in radiation oncology at Montefiore-Einstein Comprehensive Cancer Center. Further, he undertook a post-doctoral fellowship focused on HPV epidemiology and therapeutic vaccine development. Dr. Blakaj’s academic training is complemented by multiple faculty leadership and coaching certifications, which have equipped him with the strategic and educational tools to excel as a clinical and academic leader in oncology.

Experience

With over a decade of experience at The Ohio State University Comprehensive Cancer Center, Dr. Dukagjin Blakaj has held progressive leadership roles, including Director of Head & Neck/Skull Base Division, Director of Clinical Operations, and currently Vice Chair of Clinical Operations. Under his guidance, the department expanded from 13 to 51 faculty members, increased revenue by over 450%, and tripled NIH funding. He has played a pivotal role in enhancing operational efficiencies, developing data lakes for research, and implementing standardized procedures across divisions. As a fellowship director in multiple subspecialties, he has trained future leaders in radiation oncology. His innovative leadership has advanced FLASH radiotherapy, Theranostics, and multidisciplinary care models. Dr. Blakaj also serves as Co-PI on several clinical trials and large-scale grants, leading to substantial contributions in patient care and translational research. His collaborative, data-driven approach continues to drive excellence in academic medicine and clinical cancer care.

Research Interests

Dr. Dukagjin Blakaj’s research spans translational oncology, radiation therapy innovations, and molecular mechanisms of treatment resistance. He focuses extensively on head and neck, skull base, and spine malignancies, leading efforts to develop precision radiation protocols and novel therapeutic strategies. His research has garnered over $5 million in funding, supporting groundbreaking clinical trials, including studies on FLASH radiotherapy, immunotherapy combinations, and stereotactic treatments. He is Principal or Co-Investigator on numerous NIH, industry-sponsored, and institutional grants addressing treatment optimization, radio-sensitization, and rare cancer biology. His work includes building large-scale clinical databases and integrating radiomic and molecular data into patient care models. He co-leads the PARTNER protocol to create a comprehensive data lake for translational research. His commitment to collaborative research has elevated institutional trial accruals and contributed to over 200 peer-reviewed publications. Through mentorship, innovation, and cross-disciplinary collaboration, Dr. Blakaj is advancing personalized oncologic care on both clinical and molecular fronts.

Awards and Honors

Dr. Dukagjin Blakaj has received numerous prestigious awards recognizing his contributions to oncology, research, and education. Notably, he received the James Outstanding Physician Peer Award for his leadership, professionalism, and collaborative spirit. He has consistently ranked among the top 10% of most published and cited doctors on Doximity (2021–2024) and was named a Top Doctor nationally in 2021. His article in Practical Radiation Oncology was selected for Elsevier’s Head & Neck Cancer Awareness Month feature. Additional accolades include the Best Teacher Award at the Osler Board Review Course, the Samuel J. Roessler Memorial Scholarship, and multiple abstract and travel awards from ASTRO, ACRO, and other leading organizations. He was also a finalist for the 2021 International Book Awards for his leadership publication. His early academic excellence was recognized through fellowships from the American Heart Association, Howard Hughes Medical Institute, and the International Biophysical Society, setting the foundation for his distinguished career.

 Publications Top Notes

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)

Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer

Time to surgery and survival in head and neck cancer

Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

NRG-HN002: a randomized phase II trial for patients with p16-positive, non-smoking-associated, locoregionally advanced oropharyngeal cancer

Single-isocenter multitarget stereotactic radiosurgery is safe and effective in the treatment of multiple brain metastases

Molecular dynamics and thermodynamics of protein−RNA interactions: Mutation of a conserved aromatic residue modifies stacking interactions and structural adaptation in the U1A protein

Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study

Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies

A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma

Evolutionary and biophysical relationships among the papillomavirus E2 proteins

Emerging concepts and novel strategies in radiation therapy for laryngeal cancer management

A digital twin for simulating the vertebroplasty procedure and its impact on mechanical stability of vertebra in cancer patients

Conclusion

Dr. Dukagjin M. Blakaj stands as a leading force in academic radiation oncology, seamlessly integrating clinical excellence, visionary leadership, and groundbreaking research. His transformative impact at The Ohio State University has resulted in institutional growth, enriched patient care, and elevated academic standards. A dedicated mentor and educator, he has cultivated the next generation of oncology leaders through innovative fellowships and global mentorship. His expansive research portfolio spans molecular biology, clinical trials, and AI-driven data analysis, reflecting a commitment to precision medicine and translational impact. Recognized nationally and internationally for his achievements, Dr. Blakaj continues to shape the future of radiation oncology through strategic leadership, collaborative partnerships, and compassionate care. His efforts exemplify how visionary thinking, paired with operational excellence, can revolutionize patient outcomes and institutional success. Dr. Blakaj remains a beacon of excellence in medicine, embodying the ideals of academic leadership, research innovation, and unwavering dedication to improving human health.

Jessica Hassel | oncology | Best Researcher Award

Published on by Best Achievements

Prof. Jessica Hassel | oncology | Best Researcher Award

Prof. Jessica Hassel, Heidelberg University Hospital, Germany.

Prof. Dr. med. Jessica C. Hassel is a renowned expert in dermato-oncology and serves as Section Head at the National Center for Tumor Diseases (NCT), Heidelberg. With an H-index of 68, she has authored over 650 publications and is a Highly Cited Researcher. She directs the Skin Cancer Center and is a board member of CCC. Her groundbreaking work in immunotherapy and melanoma research has earned her multiple accolades, including the German Skin Cancer Award and the MSD Health Prize.

Profile

Scopus Profile

Orcid Profile

Google Scholar Profile

Yudai Shimojukkoku | Oncology | Best Researcher Award

Published on by Best Achievements

Dr. Yudai Shimojukkoku | Oncology | Best Researcher Award

Dr. Yudai Shimojukkoku, Saitama Cancer Center, Japan.

Dr. Shimojukkoku Yudai 🧑‍🔬 is a dedicated cancer researcher at Saitama Cancer Center and Kagoshima University. His work focuses on oral squamous cell carcinoma, exploring the tumor microenvironment and identifying novel biomarkers 🧫. He collaborates with renowned experts like Prof. Sasahira, advancing both basic and clinical research. His contributions aim to bridge the gap between oral health and systemic diseases such as diabetes 🦷❤️. Dr. Yudai’s research is paving the way for innovative cancer diagnostics and treatments. 🌟

Profile

SCOPUS ID

🎓 Early Academic Pursuits

Dr. Shimojukkoku Yudai embarked on his academic journey with a deep-rooted passion for medical sciences, particularly in oncology. He demonstrated an early commitment to understanding the biological mechanisms of cancer, eventually focusing his expertise on oral squamous cell carcinoma. His educational background provided a strong foundation in both clinical and molecular pathology, setting the stage for a career centered on bridging lab-based discoveries with real-world clinical applications.

💼 Professional Endeavors

Currently affiliated with the Saitama Cancer Center and Kagoshima University’s Department of Molecular and Oral Pathology, Dr. Yudai combines research with clinical responsibilities. He is deeply involved in improving diagnostic techniques and therapeutic approaches in oral cancer. His daily work integrates patient-centered care with experimental exploration, ensuring translational relevance of his research.

🔬 Contributions and Research Focus On Oncology 

Dr. Yudai’s research targets the tumor microenvironment and identification of novel biomarkers in oral cancer. He has led and participated in both in vitro and in vivo studies, as well as computational analyses (in silico) to discover two previously unidentified markers that have since influenced ongoing investigative studies. His active collaboration with renowned cancer researcher Prof. Sasahira has further enhanced his research on the link between oral cancer and periodontal disease, and the complex relationship between cancer progression and diabetes mellitus.

🌍 Impact and Influence

Although early in his career, Dr. Yudai’s work has begun to leave a significant impact in the field of oral oncology. His insights are contributing to the evolving understanding of how systemic diseases and oral cancer interact. His research, while currently limited in citation due to its recent publication, presents promising implications for clinical diagnostics and personalized cancer therapy. His focus on translational outcomes ensures his findings are poised to improve patient outcomes in the near future.

🧠 Research Skills

Dr. Yudai demonstrates a versatile skill set encompassing molecular biology, histopathology, bioinformatics, and clinical oncology. He is adept at designing and executing comprehensive experimental workflows and data interpretation. His capacity to blend clinical insights with molecular discoveries makes him a valuable asset in precision medicine research.

🏅 Awards and Honors

Dr. Yudai is actively seeking recognition in categories such as the Young Scientist Award, Best Researcher Award, Outstanding Scientist Award, and Best Research Scholar Award. His self-motivated dedication, impactful publications, and meaningful collaborations make him a strong contender for these accolades. His contributions signify excellence in early-stage cancer research.

🏛️ Legacy and Future Contributions

As he advances, Dr. Yudai aims to pioneer new diagnostic tools and therapeutic targets that can revolutionize the treatment of oral cancers. His collaborative spirit and interdisciplinary research vision promise continued contributions to global cancer research. With a commitment to both innovation and patient care, he is laying a foundation that could influence generations of oncological practice and research.

Publications Top Notes

📘 Title: MCTP2 is a novel biomarker promoting tumor progression and nodal metastasis in oral squamous cell carcinoma
🧑‍🔬 Authors: Shimojukkoku Yudai, et al.
📚 Journal: Scientific Reports
📅 Year: 2025
🔗 Link: https://www.nature.com/articles/s41598-025-02094-9 (🔒 Currently disabled)
🧬 Highlights: Introduces MCTP2 as a promising biomarker for tumor progression and nodal metastasis in oral squamous cell carcinoma.

 

Yvonne Rosenberg | Cancer | Best Researcher Award

Published on by Best Achievements

Dr. Yvonne Rosenberg | Cancer | Best Researcher Award

Dr. Yvonne Rosenberg,PlantVax Inc, United States.

🌿 Dr. Yvonne J. Rosenberg is the CEO of PlantVax Inc. and a leading expert in immunology and biotherapeutic innovation. With a Ph.D. from Australian National University, she has pioneered research in HIV immunotherapy, autoimmunity, and nerve agent antidotes. 🌍 Her work bridges basic science and translational medicine, using plant-based systems to produce cutting-edge therapies. 💉 With decades of global recognition and impactful publications, she continues to revolutionize the field of biomedical science. 🧬

Profile

Scopus profile

Orcid Profile

🎓 Early Academic Pursuits

Yvonne J. Rosenberg began her academic journey at the University of Queensland, Australia, earning a B.Sc. in Zoology (1969) and a First-Class Honours B.Sc. in Parasitology (1970). She continued to develop her scientific expertise with a Ph.D. in Immunology from Australian National University in 1976. Her foundational academic training provided a robust framework in parasitology and immunological mechanisms. Rosenberg further honed her expertise as a Visiting Fellow at the National Institutes of Health (NIH), where she focused on advanced immunological research. 🎓🔬

💼 Professional Endeavors

Dr. Rosenberg’s professional journey spans academia, industry, and biotech leadership. From her early roles as a Visiting Scientist in London to research positions at NIH and Columbia University, she moved into leadership roles at TherImmune Research Corp and ProCell Corporation. In 2007, she founded PlantVax Inc, where she currently serves as CEO. Her work reflects a seamless blend of translational research and product innovation across fields such as HIV, autoimmune disease, and biodefense. 🏢🌿

🔬 Contributions and Research Focus On Cancer 

Dr. Rosenberg’s research contributions are vast and groundbreaking. Her early work on B lymphocyte development and T cell regulation laid the groundwork for major advancements in immunology and parasitology. She transitioned into HIV pathogenesis research, utilizing macaque models to study immune responses. More recently, her focus has shifted to the development of recombinant therapeutic molecules, including broadly neutralizing HIV antibodies (bnAbs) and plant-derived cholinesterases for neurotoxin defense. 🌱🧪

🌍 Impact and Influence

Dr. Rosenberg’s research has directly impacted fields ranging from infectious diseases to neuroprotection, influencing therapeutic approaches and policy directions in HIV, autoimmunity, and biodefense. Her innovative plant-based expression systems offer cost-effective solutions with global health applications, making her work especially relevant in low-resource settings. Her translational focus has brought lab innovations closer to real-world implementation. 💡🌐

🧠 Research Skills

Dr. Rosenberg possesses expertise in molecular immunology, plant-based protein expression, animal modeling, vaccine development, and biochemical pharmacology. Her ability to translate basic research into applied therapies demonstrates her proficiency in both exploratory science and product development. Her skills extend to leadership in collaborative, interdisciplinary research initiatives. 🧬🧫

🏅 Awards and Honors

Dr. Rosenberg’s exceptional achievements have been recognized with numerous awards, including the NIH Fogarty Award, NHMRC CJ Martin Biomedical Award, and American Association of Immunologists Travel Awards. These accolades underscore her influence and sustained contributions to biomedical research at the global level. 🥇🌟

🏛️ Legacy and Future Contributions

With a career spanning decades, Dr. Rosenberg’s legacy lies in her interdisciplinary approach—blending basic immunology with translational innovation. Her pioneering use of plant systems for protein production is likely to shape the future of vaccine and therapeutic development. As she continues her leadership at PlantVax, her work promises to drive forward solutions for HIV prevention, autoimmune treatment, and chemical threat mitigation. Her contributions will resonate through both scientific literature and lifesaving applications for years to come. 🚀🌿

Publications Top Notes

📄 1. A single post-exposure oxime RS194B treatment rapidly reactivates acetylcholinesterase and reverses acute symptoms in macaques exposed to diethylphosphorothioate parathion and chlorpyrifos insecticides
📰 Journal: Journal of Neurochemistry
📅 Year: 2024
🔢 Citations: 4
🧪 Topic: Organophosphate poisoning, macaque model, oxime therapy

📄 2. The impact of solvents on the toxicity of the banned parathion insecticide
📰 Journal: Chemico-Biological Interactions
📅 Year: 2023
🔢 Citations: 3
🧪 Topic: Parathion insecticide, solvent effects, toxicology

📄 3. Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
📰 Journal: mBio
📅 Year: 2023
🔢 Citations: 8
🧬 Topic: Immunoglobulin transport, placental biology, Fc receptors

Samah Saharti | Cancer | Best Researcher Award

Published on by Best Achievements

Dr. Samah Saharti | Cancer | Best Researcher Award

Dr. Samah Saharti, King Abdulaziz University, Saudi Arabia.

Dr. Samah Nabeel M. Saharti, M.D., is an Associate Professor of Pathology at King Abdulaziz University, Jeddah, Saudi Arabia. Specializing in Molecular Genetics and Cytopathology, Dr. Saharti has completed multiple prestigious fellowships and is a certified expert in Anatomical Pathology. With numerous impactful publications and research on topics such as gynecological malignancies and leukemia, she has significantly contributed to advancing medical science. Recognized for her outstanding academic achievements, Dr. Saharti continues to shape the future of pathology and genetics. 👩‍🔬📚

Profile

Scopus Profile

Orcid Profile

🎓 Early Academic Pursuits

Dr. Samah Saharti’s academic journey began with an impressive MD degree from King Abdulaziz University School of Medicine in 2008, graduating with Honors and a high GPA of 4.27/5.00. Her foundation in medical education laid the groundwork for her pursuit of specialized training in molecular genetics, cytopathology, and surgical pathology, which were obtained through prestigious fellowships at renowned institutions like the University of Nebraska Medical Center, Loyola University, and the University of California.

💼 Professional Endeavors

Dr. Saharti has been an Associate Professor of Pathology and Consultant Pathologist at King Abdulaziz University since 2009. Her professional expertise spans molecular genetics, cytopathology, and surgical pathology, with pivotal roles in medical education as Head of Genitourinary Teaching Module and Medical Students Elective Rotation Coordinator.

🔬 Contributions and Research Focus

Dr. Saharti’s research is distinguished by its focus on molecular pathology, specifically in gynecological malignancies and colorectal cancer. She has published influential papers on topics like molecular classification of endometrial carcinoma, mismatch repair proteins, and novel gene mutations linked to leukodystrophy. Her work bridges clinical practice with advanced molecular diagnostics, providing deeper insights into cancer pathology and treatment strategies.

🏆 Awards and Honors

Dr. Samah Nabeel M. Saharti has earned numerous accolades throughout her career, reflecting her excellence in both education and research:

  • 2014: Achievement Award for Outstanding Residency Performance – Recognized for exceptional performance during her residency.
  • 2013: ASCP CheckSample Honorarium – Awarded for outstanding contributions in pathology education.
  • 2009: Post-Graduate Residency & Fellowship Training Scholarship – Acknowledged for her academic excellence and potential in advanced training.
  • 2008: Degree of Honors – Awarded to the top graduates of King Abdulaziz University School of Medicine for outstanding academic achievement.
  • 2008: Top Ten Medical Graduate Achievers – Recognized as one of the top achievers in her medical school class at King Abdulaziz University.
  • 2003: Excellent (A) GPA Award – Awarded for maintaining a top GPA during her early academic years at King Abdulaziz University School of Medicine.

These honors highlight Dr. Saharti’s unwavering commitment to excellence in the medical field.

🌍 Impact and Influence

Her leadership in molecular genetics and cytopathology is recognized both locally and internationally, shaping academic programs and contributing to the understanding of cancer biomarkers. Dr. Saharti’s involvement in global professional organizations like the Association for Molecular Pathology (AMP) and American Society for Clinical Pathology (ASCP) further underscores her impact on the field.

📖Academic Cites

Dr. Saharti’s contributions to the scientific community are widely recognized, with her research cited in leading medical journals. Her work on molecular signatures in gynecological malignancies and translocations in leukemia has been crucial in shaping contemporary pathology practices. Publications like Cytojournal, Clin. Exp. Obstet. Gynecol, and Saudi Med J illustrate the extent to which her research is referenced in the field.

🔮 Future Directions & Legacy

As a mentor and educator, Dr. Saharti’s legacy extends through her guidance of young pathologists and medical students, ensuring that her knowledge and expertise continue to shape future generations. With ongoing research and involvement in groundbreaking studies, her contributions are expected to influence genetic diagnostics and cancer treatment strategies for years to come.

Publications Top Notes

KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer

Journal: Cureus

Year: 2022

📅🔬

Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer

Journal: Journal of Obstetrics and Gynaecology

Year: 2021

📅👩‍🔬

Two Novel Homozygous HPS6 Mutations (Double Mutant) Identified by Whole-Exome Sequencing in a Saudi Consanguineous Family Suspected for Oculocutaneous Albinism

Journal: Life

Year: 2021

📅🧬

Fine-needle aspirate of the liver showing coexistence of Schistosoma japonicum ova and hepatocellular carcinoma

Journal: Diagnostic Cytopathology

Year: 2018

📅🔬

Balloon cells in metastatic melanoma

Journal: Diagnostic Cytopathology

Year: 2017

📅🔬

Aerosol transfer of bladder urothelial and smooth muscle cells onto demucosalized colonic segments for bladder augmentation: In vivo, long term, and functional pilot study

Journal: Journal of Pediatric Urology

Year: 2015

📅🔬

Wiskott-Aldrich syndrome: Description of a new gene mutation with normal platelet volume

Journal: Journal of Pediatric Hematology/Oncology

Year: 2015

📅🧬